Symmetry Partners LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 86.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 8,900 shares of the biopharmaceutical company’s stock after selling 59,226 shares during the quarter. Symmetry Partners LLC’s holdings in Pfizer were worth $320,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the company. Nuveen Asset Management LLC raised its stake in Pfizer by 2,240.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock worth $1,563,256,000 after buying an additional 34,544,423 shares during the period. Natixis bought a new position in shares of Pfizer in the second quarter valued at approximately $258,466,000. Invesco Ltd. grew its holdings in shares of Pfizer by 14.6% in the second quarter. Invesco Ltd. now owns 21,118,606 shares of the biopharmaceutical company’s stock valued at $914,857,000 after acquiring an additional 2,693,349 shares in the last quarter. DNB Asset Management AS grew its holdings in shares of Pfizer by 241.0% in the third quarter. DNB Asset Management AS now owns 3,734,044 shares of the biopharmaceutical company’s stock valued at $134,164,000 after acquiring an additional 2,638,873 shares in the last quarter. Finally, Thoroughbred Financial Services LLC grew its holdings in shares of Pfizer by 4,297.8% in the second quarter. Thoroughbred Financial Services LLC now owns 2,656,678 shares of the biopharmaceutical company’s stock valued at $265,668,000 after acquiring an additional 2,596,269 shares in the last quarter. Institutional investors own 71.52% of the company’s stock.
Several equities analysts have recently issued reports on the company. Credit Suisse Group reaffirmed a “hold” rating and issued a $41.30 target price on shares of Pfizer in a report on Wednesday. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a report on Tuesday, October 1st. UBS Group reissued a “neutral” rating and set a $43.00 price objective on shares of Pfizer in a report on Monday, August 5th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Finally, ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Nine investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $44.02.
In related news, major shareholder Pfizer Inc bought 50,000 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $900,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Scott Gottlieb bought 3,000 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were bought at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the transaction, the director now owns 3,000 shares of the company’s stock, valued at $104,160. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.
NYSE PFE traded up $0.13 on Friday, hitting $37.04. 965,488 shares of the stock traded hands, compared to its average volume of 16,850,170. The business’s fifty day moving average is $36.61 and its two-hundred day moving average is $39.27. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $46.47. The firm has a market capitalization of $207.30 billion, a price-to-earnings ratio of 12.35, a PEG ratio of 2.11 and a beta of 0.67. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.13. The firm had revenue of $12.68 billion for the quarter, compared to the consensus estimate of $12.37 billion. Pfizer had a return on equity of 28.61% and a net margin of 30.57%. The business’s quarterly revenue was down 4.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.78 earnings per share. Analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.36 per share. The ex-dividend date is Thursday, November 7th. This represents a $1.44 annualized dividend and a dividend yield of 3.89%. Pfizer’s dividend payout ratio is currently 48.00%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: S&P 500 Index
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.